Sp959
LIFTING THE MINORITY TAX
Date
May 8, 2023
Explore related products in the following collection:
Society: DDW
All symposia are 90-minute sessions, led by two moderators, with a varying number of invited talks. The session may include Q&A which can be included within each speaker’s total presentation time (2-3 minutes at the end) or as a separate block within the session. The session may also include a panel discussion with noted and/or additional speakers. Science type and topic will vary by the session sponsor.
All symposia are 90-minute sessions, led by two moderators, with a varying number of invited talks. The session may include Q&A which can be included within each speaker’s total presentation time (2-3 minutes at the end) or as a separate block within the session. The session may also include a panel discussion with noted and/or additional speakers. Science type and topic will vary by the session sponsor.
Presenter
Emory University School of Medicine
Tracks
Related Products
IMMUNE EDITING IN THE INVASIVE MARGIN AND NODE DEPOSITS OF COLORECTAL CANCER SELECTS FOR CELLULAR NEIGHBOURHOODS ENRICHED IN PDL1+ CANCER CELLS
BACKGROUND: Perianal fistulae are highly morbid complications of Crohn’s disease (CD) with a cumulative incidence of 20-25%; despite demonstrated efficacy of infliximab treatment, estimates of complete resolution are only 20-30%. Ultimately, 20% of patients will require proctectomy…
GLIAL CONNEXIN-43 HEMICHANNELS ARE CRITICAL DETERMINANTS OF GUT INFLAMMATION IN MOUSE POSTOPERATIVE ILEUS AND REACTIVE HUMAN ENTERIC GLIA
BACKGROUND: Perianal fistulae are highly morbid complications of Crohn’s disease (CD) with a cumulative incidence of 20-25%; despite demonstrated efficacy of infliximab treatment, estimates of complete resolution are only 20-30%. Ultimately, 20% of patients will require proctectomy…
MULTIMODAL SINGLE CELL ANALYSES REVEAL PATHOGENIC FIBROBLASTS IN PERIANAL FISTULA
BACKGROUND: Perianal fistulae are highly morbid complications of Crohn’s disease (CD) with a cumulative incidence of 20-25%; despite demonstrated efficacy of infliximab treatment, estimates of complete resolution are only 20-30%. Ultimately, 20% of patients will require proctectomy…
THE ROLE OF ENTERIC GLIAL CELLS AND AQP1 IN THE AMELIORATING EFFECT OF ELECTROACUPUNCTURE IN A RODENT MODEL OF VISCERAL HYPERSENSITIVITY
BACKGROUND: Perianal fistulae are highly morbid complications of Crohn’s disease (CD) with a cumulative incidence of 20-25%; despite demonstrated efficacy of infliximab treatment, estimates of complete resolution are only 20-30%. Ultimately, 20% of patients will require proctectomy…
